Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study.
McCarter KR, Wolfgang T, Arabelovic S, Wang X, Yoshida K, Banasiak EP, Qian G, Kowalski EN, Vanni KMM, LeBoeuf NR, Buchbinder EI, Gedmintas L, MacFarlane LA, Rao DA, Shadick NA, Gravallese EM, Sparks JA.
Lancet Rheumatol. 2023 May;5(5):e274-e283. doi: 10.1016/s2665-9913(23)00064-4. Epub 2023 Mar 27.
Multifunctional nanoparticle-mediated combining therapy for human diseases.
Li X, Peng X, Zoulikha M, Boafo GF, Magar KT, Ju Y, He W.
Signal Transduct Target Ther. 2024 Jan 1;9(1):1. doi: 10.1038/s41392-023-01668-1.
PMID:38161204
Eyes and the heart: what a clinician should know.
Ng JY, Zarook E, Nicholson L; Oculi-Cordis group; Khanji MY, Chahal CAA.
Heart. 2023 Oct 26;109(22):1670-1676. doi: 10.1136/heartjnl-2022-322081.
PMID:37507215
Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events.
Fa'ak F, Buni M, Falohun A, Lu H, Song J, Johnson DH, Zobniw CM, Trinh VA, Awiwi MO, Tahon NH, Elsayes KM, Ludford K, Montazari EJ, Chernis J, Dimitrova M, Sandigursky S, Sparks JA, Abu-Shawer O, Rahma O, Thanarajasingam U, Zeman AM, Talukder R, Singh N, Chung SH, Grivas P, Daher M, Abudayyeh A, Osman I, Weber J, Tayar JH, Suarez-Almazor ME, Abdel-Wahab N, Diab A.